Literature DB >> 34800368

Type I interferon activates MHC class I-dressed CD11b+ conventional dendritic cells to promote protective anti-tumor CD8+ T cell immunity.

Ellen Duong1, Tim B Fessenden2, Emi Lutz3, Teresa Dinter1, Leon Yim2, Sarah Blatt2, Arjun Bhutkar2, Karl Dane Wittrup3, Stefani Spranger4.   

Abstract

Tumor-infiltrating dendritic cells (DCs) assume varied functional states that impact anti-tumor immunity. To delineate the DC states associated with productive anti-tumor T cell immunity, we compared spontaneously regressing and progressing tumors. Tumor-reactive CD8+ T cell responses in Batf3-/- mice lacking type 1 DCs (DC1s) were lost in progressor tumors but preserved in regressor tumors. Transcriptional profiling of intra-tumoral DCs within regressor tumors revealed an activation state of CD11b+ conventional DCs (DC2s) characterized by expression of interferon (IFN)-stimulated genes (ISGs) (ISG+ DCs). ISG+ DC-activated CD8+ T cells ex vivo comparably to DC1. Unlike cross-presenting DC1, ISG+ DCs acquired and presented intact tumor-derived peptide-major histocompatibility complex class I (MHC class I) complexes. Constitutive type I IFN production by regressor tumors drove the ISG+ DC state, and activation of MHC class I-dressed ISG+ DCs by exogenous IFN-β rescued anti-tumor immunity against progressor tumors in Batf3-/- mice. The ISG+ DC gene signature is detectable in human tumors. Engaging this functional DC state may present an approach for the treatment of human disease.
Copyright © 2021 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  MHC class I dressing; T cell exhaustion; anti-tumor immunity; cross-presentation; dendritic cells; immunotherapy; optimal anti-tumor immunity; tumor regression; type 2 dendritic cells; type I interferon

Mesh:

Substances:

Year:  2021        PMID: 34800368     DOI: 10.1016/j.immuni.2021.10.020

Source DB:  PubMed          Journal:  Immunity        ISSN: 1074-7613            Impact factor:   31.745


  21 in total

Review 1.  Chemo- and mechanosensing by dendritic cells facilitate antigen surveillance in the spleen.

Authors:  Dan Liu; Lihui Duan; Jason G Cyster
Journal:  Immunol Rev       Date:  2022-03       Impact factor: 12.988

Review 2.  Cancer vaccines: Building a bridge over troubled waters.

Authors:  MacLean C Sellars; Catherine J Wu; Edward F Fritsch
Journal:  Cell       Date:  2022-07-13       Impact factor: 66.850

Review 3.  Novel targets for immunotherapy associated with exhausted CD8 + T cells in cancer.

Authors:  Lulu Zhang; Bo Zhang; Lin Li; Yingchun Ye; Yuchuan Wu; Qing Yuan; Wenfeng Xu; Xue Wen; Xiyuan Guo; Siji Nian
Journal:  J Cancer Res Clin Oncol       Date:  2022-09-15       Impact factor: 4.322

4.  Alum-anchored intratumoral retention improves the tolerability and antitumor efficacy of type I interferon therapies.

Authors:  Emi A Lutz; Yash Agarwal; Noor Momin; Sarah C Cowles; Joseph R Palmeri; Ellen Duong; Vladlena Hornet; Allison Sheen; Brianna M Lax; Adrienne M Rothschilds; Darrell J Irvine; Stefani Spranger; K Dane Wittrup
Journal:  Proc Natl Acad Sci U S A       Date:  2022-08-29       Impact factor: 12.779

Review 5.  Dendritic Cell-Based Immunotherapy in Hot and Cold Tumors.

Authors:  Byeong Hoon Kang; Heung Kyu Lee
Journal:  Int J Mol Sci       Date:  2022-06-30       Impact factor: 6.208

6.  Huaier Induces Immunogenic Cell Death Via CircCLASP1/PKR/eIF2α Signaling Pathway in Triple Negative Breast Cancer.

Authors:  Chen Li; Xiaolong Wang; Tong Chen; Wenhao Li; Xianyong Zhou; Lishui Wang; Qifeng Yang
Journal:  Front Cell Dev Biol       Date:  2022-06-16

7.  Localized ablative immunotherapy drives de novo CD8+ T-cell responses to poorly immunogenic tumors.

Authors:  Ashley R Hoover; Saghar Kaabinejadian; Jason R Krawic; Xiao-Hong Sun; Abdul Rafeh Naqash; Qian Yin; Xinbo Yang; K Christopher Garcia; Mark M Davis; William H Hildebrand; Wei R Chen
Journal:  J Immunother Cancer       Date:  2022-10       Impact factor: 12.469

Review 8.  Epigenetics of Dendritic Cells in Tumor Immunology.

Authors:  Gerard Godoy-Tena; Esteban Ballestar
Journal:  Cancers (Basel)       Date:  2022-02-24       Impact factor: 6.639

Review 9.  Dendritic Cell-Based Immunotherapy in Multiple Myeloma: Challenges, Opportunities, and Future Directions.

Authors:  Emma Verheye; Jesús Bravo Melgar; Sofie Deschoemaeker; Geert Raes; Anke Maes; Elke De Bruyne; Eline Menu; Karin Vanderkerken; Damya Laoui; Kim De Veirman
Journal:  Int J Mol Sci       Date:  2022-01-14       Impact factor: 5.923

Review 10.  Plasmacytoid Dendritic Cells and Cancer Immunotherapy.

Authors:  Chunmei Fu; Li Zhou; Qing-Sheng Mi; Aimin Jiang
Journal:  Cells       Date:  2022-01-11       Impact factor: 6.600

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.